Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.75 |
| ▸ | DRD2 | P14416 | 4/20 | 0.70 |
| ▸ | DRD3 | P35462 | 3/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.62 |
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588149 | 0.89 | DRD4 (1.00) | DRD4SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL6794331 | 0.89 | DRD4 (0.79) | DRD4SIGMAR1DRD2DRD3ALDH1A1 | |
| SCHEMBL22532699 | 0.89 | DRD4 (0.79) | DRD4SIGMAR1DRD2DRD3HTR1A | |
| SCHEMBL12861757 | 0.89 | DRD4 (0.79) | DRD4SIGMAR1DRD2DRD3HTR1A | |
| SCHEMBL4649494 | 0.89 | DRD4 (0.87) | DRD4SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL3242189 | 0.87 | DRD4 (0.77) | DRD4SIGMAR1DRD2DRD3HTR1A | |
| SCHEMBL7604485 | 0.87 | DRD4 (0.77) | DRD4SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL3242187 | 0.87 | DRD4 (0.77) | DRD4SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL654308 | 0.87 | DRD4 (0.77) | DRD4SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL5986956 | 0.87 | DRD4 (0.77) | DRD4SIGMAR1DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5817489-A | BACTERICIDES, OR CHEMICAL INTERMEDIATES THEREOF; DRUG LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-06 | — | — | US | claimed |
| US-20230127728-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | CANON KK (JP) | 2023-04-27 | — | — | US | disclosed |
| US-11518889-B2 | Modified graphene, method of producing modified graphene, modified graphene-resin composite, modified graphene sheet, and modified graphene dispersion | CANON KABUSHIKI KAISHA (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20200270463-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | CANON KABUSHIKI KAISHA (JP) | 2020-08-27 | — | — | US | disclosed |
| CN-108239772-B | Corrosion inhibitor for oil-water interface of ground gathering and transportation system and preparation method thereof | 中国石油天然气股份有限公司 | 2020-03-10 | — | — | CN | disclosed |
| US-20180118700-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2018-05-03 | — | — | US | disclosed |
| US-20180078548-A1 | Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2018-03-22 | — | — | US | disclosed |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9442399-B2 | Electrophotographic photosensitive member, process cartridge, electrophotographic apparatus and phthalocyanine crystal | CANON KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9442399-B2 | Electrophotographic photosensitive member, process cartridge, electrophotographic apparatus and phthalocyanine crystal | CANON KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| US-5817489-A | BACTERICIDES, OR CHEMICAL INTERMEDIATES THEREOF; DRUG LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5798360-A | ANTIBACTERIAL AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| WO-1998033784-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5780241-A | ALTERING ELECTROCHEMICAL PROPERTIES BY DECYCLIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020349-A1 | COMPLEX CHEMICAL LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| US-5731438-A | BACTERICIDES; DRUGS | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1998008091-A1 | NORMALIZATION OF COMBINATORIAL REACTIONS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| WO-1998005332-A1 | NOVEL HETEROCYCLE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1996016057-A1 | CERTAIN 1-SUBSTITUTED AMINOMETHYL IMIDAZOLE AND PYRROLE DERIVATIVES; NOVEL DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0159566-A1 | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient | KANEBO, LTD. (JP) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118700-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | VDAC1, VDAC2, VDAC3 | DRD4 1928/4885SIGMAR1 2880/4885DRD2 1046/4885 |
| US-20200270463-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | GRIA1, GRIN1, NR3C1 | DRD4 105/4885SIGMAR1 844/4885DRD2 243/4885 |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | DRD4 533/4885SIGMAR1 3/4885DRD2 164/4885 |
| US-20230127728-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | GRIA1, GRIN1, NR3C1 | DRD4 109/4885SIGMAR1 835/4885DRD2 244/4885 |
| US-20180078548-A1 | Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors | VDAC2, VDAC3, VDAC1 | DRD4 950/4885SIGMAR1 1219/4885DRD2 427/4885 |
| US-11518889-B2 | Modified graphene, method of producing modified graphene, modified graphene-resin composite, modified graphene sheet, and modified graphene dispersion | GRIA1, GRIN1, NR3C1 | DRD4 105/4885SIGMAR1 844/4885DRD2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.